Prevention of unfavorable fibrin clots and thrombo-embolic manifestations in patients with cardiovascular disease.

INTRODUCTION

Compelling evidence shows that unfavorably altered (prothrombotic) fibrin clot properties such as more compact and poorly lysable fibrin networks contribute to thrombo-embolic events in cardiovascular disease.

AREAS COVERED

Following a literature search in Medline, Embase, TRIP, and the Cochrane Database of Systematic Reviews, this review summarizes the current evidence on therapeutic strategies, that are currently used or tested in cardiovascular disease including coronary artery disease, peripheral artery disease, atrial fibrillation, heart failure, and their thrombotic manifestations, in particular myocardial infarction and ischemic stroke, in the context of altered plasma fibrin clot characteristics.

EXPERT OPINION

Anticoagulants (heparins, vitamin K antagonists, and direct oral anticoagulants), aspirin, and statins favorably modify fibrin clot characteristics, which might contribute to their efficacy in various clinical settings. Encouraging results suggest that novel treatments not yet approved in cardiovascular disease, including factor XI inhibitors and lipoprotein (a) reducing agents, might be beneficial, in part through improved fibrin clot phenotype, which gives hope for reducing the residual risk of thromboembolism in cardiovascular disease, which persists despite the recommended management.